Tislelizumab
Monoclonal antibody | |
---|---|
Type | Whole antibody |
Source | Humanized |
Target | PD-1 |
Clinical data | |
Synonyms | BGB-A317 |
ATC code |
|
Identifiers | |
ChemSpider |
|
Tislelizumab[1][2] (BGB-A317) is a humanized monoclonal antibody directed against PD-1.[3] It prevents PD-1 from binding to the ligands PD-L1 and PD-L2 (hence it is a checkpoint inhibitor). It is being investigated as a treatment for advanced solid tumors.[3]
It is designed to bind less to Fc gamma receptors.[4]
It is being developed by BeiGene and Celgene Corp.[5]
Clinical trials
Phase I trials began in the US and Australia in June 2015 and were expected to complete in mid-2017.[6] Some early results were announced in July 2016.[7][3]
A pivotal phase 2 clinical trial for urothelial cancer started in China in 2017.[4]
It is in a phase 3 trial for NSCLC.[8]
A multicenter phase 3 trial for advanced hepatocellular carcinoma started in Jan 2018.[5]
Pharmacokinetics
Early phase I clinical trial results give an elimination half-life of 11 to 17 days.[3]
References
- ↑ BGB-A317
- ↑ BeiGene Presents Initial Phase 1b Data for BTK Inhibitor Zanubrutinib (BGB-3111) Combined with PD-1 Antibody Tislelizumab (BGB-A317) ... Dec 2017
- 1 2 3 4 A phase I dose-escalation study of BGB-A317, an anti-programmed death-1 (PD-1) mAb in patients with advanced solid tumors. ASCO 2016
- 1 2 BeiGene (BGNE) Commences Pivotal Trial of PD-1 Antibody BGB-A317 in China in Patients with Urothelial Cancer. July 2017
- 1 2 BeiGene Initiates Global Phase 3 Trial of Anti-PD-1 Antibody Tislelizumab in Patients with Hepatocellular Carcinoma Jan 2018
- ↑ Study of the Safety, Pharmacokinetics and Antitumor Activities of BGB-A317 in Subjects With Advanced Tumors
- ↑ Early Results of Immunotherapy Study Showing Anti-Cancer Activity in Range of Solid Tumors July 2016
- ↑ Comparison of Efficacy and Safety of Anti-PD-1 Antibody BGB-A317 Versus Docetaxel as Treatment in the Second- or Third-line Setting in Patients With NSCLC